Aclaris Therapeutics Inc (NASDAQ: ACRS) on Friday, soared 6.42% from the previous trading day, before settling in for the closing price of $1.87. Within the past 52 weeks, ACRS’s price has moved between $1.05 and $5.17.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 15.24%. The company achieved an average annual earnings per share of 70.18%. With a float of $92.29 million, this company’s outstanding shares have now reached $108.33 million.
Aclaris Therapeutics Inc (ACRS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Aclaris Therapeutics Inc is 14.81%, while institutional ownership is 72.89%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares.
Aclaris Therapeutics Inc (ACRS) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.11 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.01) by -0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 70.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.56% during the next five years compared to 15.24% growth over the previous five years of trading.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Aclaris Therapeutics Inc (ACRS) is currently performing well based on its current performance indicators. A quick ratio of 3.88 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.37, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.53 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
The latest stats from [Aclaris Therapeutics Inc, ACRS] show that its last 5-days average volume of 0.84 million was inferior to 0.97 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 53.27%.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 83.42%, which indicates a significant increase from 52.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1154 in the past 14 days, which was higher than the 0.1005 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7916, while its 200-day Moving Average is $1.8423. Now, the first resistance to watch is $2.0233. This is followed by the second major resistance level at $2.0567. The third major resistance level sits at $2.1233. If the price goes on to break the first support level at $1.9233, it is likely to go to the next support level at $1.8567. Assuming the price breaks the second support level, the third support level stands at $1.8233.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
Market capitalization of the company is 215.58 million based on 108,332K outstanding shares. Right now, sales total 18,720 K and income totals -132,070 K. The company made 1,780 K in profit during its latest quarter, and -15,430 K in sales during its previous quarter.
